Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H35NO2 |
Molecular Weight | 429.5937 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C3=CC=C(C=C3)N(C)C)C4=C5CCC(=O)C=C5CC[C@@]24[H]
InChI
InChIKey=VKHAHZOOUSRJNA-GCNJZUOMSA-N
InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
Molecular Formula | C29H35NO2 |
Molecular Weight | 429.5937 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00834Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/cdi/mifepristone.html
Sources: http://www.drugbank.ca/drugs/DB00834
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/cdi/mifepristone.html
Mifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol. The anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results. In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels. Mifepristone is used for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24778047
Curator's Comment: mifepristone does cross the blood-brain barrier
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL208 Sources: http://www.drugbank.ca/drugs/DB00834 |
0.35 nM [IC50] | ||
Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00834 |
0.8 nM [IC50] | ||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8627601 |
5.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | MIFEPREX Approved UseMIFEPREX is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation. Launch Date2000 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.77 mg/L |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
MIFEPRISTONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25.8 mg × h/L |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
MIFEPRISTONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
MIFEPRISTONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0 |
inconclusive [IC50 >10 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0 |
inconclusive [IC50 >10 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0 |
yes [IC50 1 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=32 Page: 32.0 |
yes [IC50 1.8 uM] | yes (co-administration study) Comment: The sponsor reported that Cmax values of digoxin were increased when digoxin was administered with the first dose (ratio, 1.68, CI, 1.54-1.84) and the last dose of mifepristone (ratio, 1.64, CI, 1.50-1.79). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=32 Page: 32.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=102 Page: 102.0 |
yes [IC50 3 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
yes [IC50 3 uM] | yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
yes [IC50 3.5 uM] | yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0 |
yes [IC50 4.3 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=32 Page: 32.0 |
yes [IC50 5.6 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
yes [IC50 6.7 uM] | yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0 |
yes [IC50 67 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0 |
yes [IC50 70 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
yes [IC50 8.5 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
yes [IC50 8.5 uM] | |||
Page: 11.0 |
yes [IC50 8.6 uM] | yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Page: 11.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
yes [IC50 8.6 uM] | yes (co-administration study) Comment: AUC0-72 hr of alprazolam and 4-OH alprazolam following 1 mg of alprazolam increased 80% (n=16) and 76% (n=16) , respectively with concomitant administration of multiple doses of 1200 mg/day mifepristone for 10 days compared to those following 1 mg of alprazolam alone. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
yes [IC50 8.7 uM] | yes (co-administration study) Comment: AUC0-72 hr of alprazolam and 4-OH alprazolam following 1 mg of alprazolam increased 80% (n=16) and 76% (n=16) , respectively with concomitant administration of multiple doses of 1200 mg/day mifepristone for 10 days compared to those following 1 mg of alprazolam alone. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0 |
yes [IC50 9.1 uM] | |||
Page: 11.0 |
yes [IC50 >10 uM] | yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Page: 11.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0 |
yes [IC50 >50 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=25 Page: 25.0 |
yes [Ki 4.7 uM] | yes (co-administration study) Comment: AUC0-72 hr of alprazolam and 4-OH alprazolam following 1 mg of alprazolam increased 80% (n=16) and 76% (n=16) , respectively with concomitant administration of multiple doses of 1200 mg/day mifepristone for 10 days compared to those following 1 mg of alprazolam alone. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=25 Page: 25.0 |
||
Page: 11.0 |
yes | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0 |
yes | |||
Page: 10.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=25 Page: 25.0 |
minor | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=25 Page: 25.0 |
minor | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=10 Page: 10.0 |
yes | |||
Page: 15.0 |
yes | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=10 Page: 10.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=18 Page: 18.0 |
||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=18 Page: 18.0 |
PubMed
Title | Date | PubMed |
---|---|---|
[Study of histopathology of endometrium following termination of early pregnancy using mifepristone]. | 1999 May |
|
Timing of pain and bleeding after mifepristone-induced abortion. | 2000 Dec |
|
Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. | 2000 May |
|
Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. | 2002 May |
|
Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs. | 2003 Jan |
|
Glucocorticoids play a fundamental role in protecting the brain during innate immune response. | 2003 Jul 2 |
|
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) stimulates gonadotropin secretion in the immature female Sprague-Dawley rat through a pentobarbital- and estradiol-sensitive mechanism but does not alter gonadotropin-releasing hormone (GnRH) secretion by immortalized GnRH neurons in vitro. | 2003 Jun |
|
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. | 2004 Aug 12 |
|
Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconeogenesis and glutamine metabolism. | 2004 Dec |
|
Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors. | 2004 Feb |
|
The unusual binding properties of the third distinct teleost estrogen receptor subtype ERbetaa are accompanied by highly conserved amino acid changes in the ligand binding domain. | 2004 Jun |
|
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. | 2004 Nov |
|
Induction of thymocyte apoptosis by systemic administration of concanavalin A in mice: role of TNF-alpha, IFN-gamma and glucocorticoids. | 2005 Aug |
|
Dissociated glucocorticoids equipotently inhibit cytokine- and cAMP-induced matrix degrading proteases in rat mesangial cells. | 2005 Aug 1 |
|
p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. | 2005 Feb |
|
The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. | 2005 Feb |
|
Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol--United States and Canada, 2001-2005. | 2005 Jul 29 |
|
The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. | 2005 Jun |
|
Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. | 2005 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/mifepristone.html
Usual Adult Dose for Abortion
-Day One: 200 mg mifepristone (MIFEPREX) orally as a single dose
-Day Two or Three: 800 mcg misoprostol buccally 24 to 48 hours after the first dose of mifepristone (Two 200 mcg misoprostol tablets should be placed in each cheek pouch [the area between the cheek and gums] for 30 minutes and then swallow any remnants with water or another liquid).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27001000
Exposure to a low concentration (0.5uM) of mifepristone during the receptive period successfully inhibits human embryo implantation process in vitro.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:20:50 GMT 2023
by
admin
on
Sat Dec 16 17:20:50 GMT 2023
|
Record UNII |
320T6RNW1F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000000115
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
FDA ORPHAN DRUG |
196304
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
22.1 (MIF/MIS)
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/05/298
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
WHO-ATC |
G03XB01
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
FDA ORPHAN DRUG |
506015
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
LIVERTOX |
NBK548328
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
NCI_THESAURUS |
C1891
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
NDF-RT |
N0000175841
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
WHO-VATC |
QG03XB01
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
WHO-ATC |
G03XB51
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
||
|
FDA ORPHAN DRUG |
239507
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
MIFEPRISTONE
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
SUB08956MIG
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
C655
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
DTXSID5023322
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
100000080629
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
1443759
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
320T6RNW1F
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
1805
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
m7536
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1276308
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
2805
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
Mifepristone
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
759862
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
5752
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
55245
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
DB00834
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
D015735
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
320T6RNW1F
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
6841
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
KK-48
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
84371-65-3
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
50692
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | |||
|
6964
Created by
admin on Sat Dec 16 17:20:51 GMT 2023 , Edited by admin on Sat Dec 16 17:20:51 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
Binding to the latter protein is saturable, and the drug displays nonlinear kinetics with respect to plasma concentration and clearance.
BINDING
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||